2021 American Transplant Congress
Evaluation and Experience with Hepatitis C Positive to Negative PancreasTransplantation
Medstar Georgetown University Hospital, Washington, DC
*Purpose: The use of hepatitis C virus (HCV) positive organs for transplant to HCV negative recipients has been reported on and has gained popularity across…2021 American Transplant Congress
Successful Single-Center Experience Using HCV+ Organs for Single and Dual-Organ Transplantation
*Purpose: National data demonstrate that increasing organ transplantation opportunities exist from hepatitis C virus (HCV)-infected individuals to HCV negative recipients.*Methods: We developed a clinical practice…2021 American Transplant Congress
T Cell Repertoire Diversity in HCV-Associated Hepatocellular Carcinoma Patients Waitlisted for Liver Transplantation and Receiving Liver-Directed Therapy
Ochsner Health, New Orleans, LA
*Purpose: T cell receptor (TCR) sequencing in hepatocellular carcinoma (HCC) patients revealed a diverse TCR repertoire in hepatitis B-associated HCC-infiltrating T cells. In this study,…2021 American Transplant Congress
Processes to Successfully Utilize Hepatitis C (HCV) Infected Donor Kidneys as Standard of Care
*Purpose: Despite robust evidence supporting the safety and efficacy of HCV-infected donor kidneys, great heterogeneity continues to exist regarding centers willingness to utilize these in…2021 American Transplant Congress
Comparison of Outcomes of Hepatitis C Virus (hcv) Nucleic Acid (nat) Positive Donor Between Hcv-naïVe and Hcv + Recpients – A Donor Mate Analysis
University of Virginia, Charlottesville, VA
*Purpose: Despite a growing mismatch between organ need and supply, organs from HCV+ donors were only offered to HCV+ recipients (HCV R+) to avoid complications…2021 American Transplant Congress
Not Always as it Seems: Lack of Hepatitis C Virus Transmission from Nucleic Acid Testing Positive Deceased Donors
1Medicine, University of Virginia, Charlottesville, VA, 2University of Virginia, Charlottesville, VA
*Purpose: Hepatitis C virus (HCV) + organs are increasingly use to transplant HCV naive candidates with good short-term outcomes. HCV transmission with HCV nucleic acid…2021 American Transplant Congress
Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients
*Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…2021 American Transplant Congress
Transplantation of Hepatitis C Positive Kidney and Pancreas Allografts Into Hepatitis C Naïve Recipients – A Single Center Experience as a Standard of Care
*Purpose: Transplantation of Hepatitis C positive organs into Hepatitis C naïve recipients is rapidly gaining widespread acceptance. We report our experience with transplanting HCV D+/R-…2021 American Transplant Congress
One-year Outcomes of a Multicenter Trial of Transplantation of Hcv Viremic Kidney Donors into Hcv Uninfected Recipients
*Purpose: As interest in transplantation of Hepatitis C virus (HCV)-viremic kidneys into HCV-uninfected (HCV+ to HCV- KT) recipients increases, understanding clinical outcomes beyond HCV clearance…2021 American Transplant Congress
Exploring the Correlation with Donor Hepatitis C Viral Load and Viral Kinetics in Naïve Kidney Transplantation Recipients
*Purpose: The transplantation of Hepatitis C viremic (HCV) kidneys into uninfected recipients was made possible by effective direct acting anti-viral (DAA) therapy. This study aims…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 28
- Next Page »